NEXSTIM CORPORATION GIVES UPDATE TO PILOT STUDY FOR CHRONIC PAIN TREATMENT HELSINKI UNIVERSITY HOSPITAL
Company announcement, Insider information, Helsinki, September 29, 2021 at 1 p.m.5.00 (EET)
Nexstim Corporation (NXTMH: HEX, NXTMS: STO) (“Nexstim” or “Company”) provides an update to a pilot study on the use of the accelerated iTBS protocol in the treatment of chronic neuropathic pain with Nexstim NBT® System at Helsinki University Hospital.
Treatment of all but one patient has been completed in five patient trials by the end of Q3 2021. Nexstim welcomes the progress of the pilot study in the current exceptional circumstances caused by the COVID-19 pandemic.
Accelerated iTBS stands for Transcranial Magnetic Stimulation (TMS), where stimulation is given several times a day over individual days. In traditional TMS treatment for pain, stimulation is given once a day for several weeks.
In Helsinki University Hospital in a pilot study, the effectiveness of the accelerated iTBS protocol is tested in five patients. They suffer from treatment-resistant, chronic neuropathic pain and have not benefited from previous 10 Hz rTMS treatment targeted to the motor cortex.
Nexstim had previously reported July 1, 2021that the treatment of the pilot patients had started as planned and that several patients had completed the treatment. At that time Nexstim estimates that patient care will continue during Q3 2021.
As previously announced, the results of the pilot study will be made public when available.
For more information, visit www.nexstim.com or contact:
Mikko Karvinen, managing director
+358 50326 4101
[email protected]
Erik Penser Bank AB (Certified Advisor)
+46 8463 83 00
[email protected]
About Nexstim Corporation
Nexstim is a Finnish, globally operating medical technology company. Our mission is to enable individual and effective treatments and diagnostics for challenging brain diseases and disorders.
Nexstim has developed a world-leading non-invasive brain stimulation technology called SmartFocus®. It is a navigated transcranial magnetic stimulation technology (nTMS) with highly advanced 3D navigation that provides accurate and individual targeting of TMS to a specific area of the brain.
SmartFocus® technology is used in Nexstim’s proprietary NTG system (NBT®), an FDA-approved marketing and commercial distribution for the treatment of major depression (MDD) United States. In Europe, The NBT® system is CE marked for the treatment of major depression and chronic neuropathic pain.
In addition, Nexstim is commercializing a SmartFocus®-based navigable brain stimulation system (NBS) for diagnostic applications. The NBS system is the only FDA-approved and CE-marked navigated TMS system for surgical pre-mapping of the speech and cortical cortex. Nexstim The shares are listed on Nasdaq First North Growth Market Finland and Nasdaq First North Growth Market Sweden.
© OMX, source GlobeNewswire – EU press releases
